Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: Cu-based bulk amorphous alloys in the quaternary Cu—Zr—Hf—Al alloy system are disclosed. A method of casting such alloys and articles comprising such alloys also are disclosed.

Abstract: A vacuum formed, tamper resistant container resists deformation of the sides thereof that might otherwise permit access to contents of the container without removal of the lid. Downward protruding lid features reinforce the wall of the container base, and buttress features included in the rim of the base extend from a base flange diagonally downward and inward to the inner rim of a recessed shelf, thereby resisting downward rotation of the wall beneath the lid protruding features. In embodiments, attachment tabs surrounded by frangible boundaries are incorporated in the lid and attached to the base by living hinges, such that removal of the lid requires breaking of the frangible boundaries and detachment of the lid from the attachment tabs. Pucker elements associated with the attachment tabs can cause the attachment tabs to pivot away from the lid when the attachment tabs are detached from the lid.

Abstract: Various exemplary drug delivery devices with on-board drug destruction, drug products utilizing the same, and methods of using drug delivery devices with on-board drug destruction are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom into a nose includes a destruction mechanism configured to destroy drug contained in the drug delivery device. The destruction mechanism can be configured to destroy the drug before a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug contained in the drug delivery device. Alternatively or in addition, the destruction mechanism can be configured to destroy the drug after a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug remaining in the drug delivery device.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).

Abstract: A system receives a specification of a circuit design for performing simulation of the circuit design. The specification includes one or more prototyping statements. A prototyping statement is processed by simulation of the circuit design. The system generates a netlist graph based on the specification of the circuit design. The system ignores the prototyping statements while generating the netlist graph. The system modifies the netlist graph to incorporate the prototyping statements of the specification. The netlist graph is modified by adding at least a net to the netlist graph based on a prototyping statement. The system performs static analysis based on the modified netlist graph.

Abstract: The present invention provides a simple, cost effective and hassle-free method and apparatus for modifying the surface grain structure of the material, thereby providing a material with multi-modal grain structure having high strength and good formability. The present invention uses a single step processing technique known as submerged static friction stir processing for modifying the surface grain structure of the material, thereby generating a multi-modal grain structure. In the present invention since the working material is completely immersed in the coolant, this maintains the working temperature of the system. Further the present invention does not involve long processing steps and do not need any specialized equipments.

Abstract: In general, methods, systems, and devices for remote aggregation of data for drug administration devices are provided. In one exemplary embodiment, data indicative of information sensed with a sensor of a drug administration device can be wirelessly transmitted from a drug administration device to a server. The server can use the data to correlate the patients use of the drug with the patients clinical outcome, perform a cost analysis of the patients treatment, determine whether the drug was delivered to the patient in compliance with the patients treatment plan, identify a malfunction in the administration of the drug, determine that additional data is needed from the drug administration device and trigger a request for the additional data to be wirelessly transmitted from the server to the drug administration device, and/or predictively model the patients clinical outcome.

Abstract: There is disclosed in one example a computing apparatus, including: a hardware platform including a processor and a memory; and instructions encoded within the memory to instruct the processor to: provide a permission list; allocate an executable, the executable to have permissions according to the permission list; designate a child object of the executable; allocate a certificate for the child object; and after a system reboot, grant the child object permissions of the executable after validating the certificate.

Abstract: Techniques of configuring settings for automatic update of calendar items in an electronic calendar systems are disclosed herein. In one embodiment, a server can receive and store update configuration records indicating that a change to a start date, start time, an end date, an end time, or location of a meeting would render a meeting update actionable. Upon receiving an incoming meeting update, the server can determine whether the incoming meeting update contains a change to one of a start date, start time, an end date, an end time or location. If true, the server can automatically modify, without any input from the recipient, a scheduled meeting appointment in the calendar folder of the recipient according to the received incoming meeting update.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: In general, drug administration devices configured to communicate with networks and external devices are provided. In an exemplary embodiment, a drug administration device is configured to adjust an operational parameter of the drug administration device based on a data packet formed from drug administration data ancillary data received from networks and/or external devices. In another example embodiment, a drug administration device is configured to scan for and establish communications with at least one external device. In another example embodiment, a method includes assessing whether to update a control program on a drug administration device from a network or external device. In another example embodiment, a system includes a first drug administration device configured to communicate with a second drug administration device to optimize a drug treatment.

Abstract: Techniques of configuring settings for automatic update of calendar items in an electronic calendar systems are disclosed herein. In one embodiment, a server can receive and store update configuration records indicating that a change to a start date, start time, an end date, an end time, or location of a meeting would render a meeting update actionable. Upon receiving an incoming meeting update, the server can determine whether the incoming meeting update contains a change to one of a start date, start time, an end date, an end time or location. If true, the server can automatically modify, without any input from the recipient, a scheduled meeting appointment in the calendar folder of the recipient according to the received incoming meeting update.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present disclosure relates to drug administration. In an exemplary embodiment, a system can include a drug administration device configured to dispense a drug to a patient, a monitoring device configured to log a delivery event of drug delivery from the drug administration device into the patient, and a sensor configured to sense a patient parameter following delivery of the drug into the patient. In another exemplary embodiment, a drug administration device can include a drug holder configured to hold a drug, a dispensing mechanism configured to dispense the drug, and a sensor configured to sense a patient parameter, and the drug administration device can be configured to locally activate the drug at a target location in the patient. In another exemplary embodiment, methods, devices, and systems are provided to assess when operation of a drug dispensing mechanism is complete and to confirm whether drug administration was successful.

Abstract: A system and method are provided for automated testing. The method includes connecting to a plurality of testing frameworks, receiving first test data and a first test state from a first testing framework of the plurality of testing frameworks, storing the first test data and the first test state in a test repository, providing the first test data and the first test state from the test repository to a second testing framework of the plurality of testing frameworks, receiving second test data and a second test state from the second testing framework, storing the second test data and the second test state in the test repository in association with the first test data, and providing access to the test repository upon completion of the multi-stage test or a set of all distinct tests on the application under test.